Stockreport

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

Redhill Biopharma Ltd. - American Depositary Shares  (RDHL) 
US:NASDAQ Investor Relations: ir.redhillbio.com/investor-relations
PDF Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a thera [Read more]